Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
The crucial role of muscle glucocorticoid signaling in accelerating obesity and glucose intolerance via hyperinsulinemia
Hiroki Yamazaki, Masaaki Uehara, Noritada Yoshikawa, Akiko Kuribara-Souta, Motohisa Yamamoto, Yasuko Hirakawa, Yasuaki Kabe, Makoto Suematsu, Hirotoshi Tanaka
Hiroki Yamazaki, Masaaki Uehara, Noritada Yoshikawa, Akiko Kuribara-Souta, Motohisa Yamamoto, Yasuko Hirakawa, Yasuaki Kabe, Makoto Suematsu, Hirotoshi Tanaka
View: Text | PDF
Research Article Endocrinology Muscle biology

The crucial role of muscle glucocorticoid signaling in accelerating obesity and glucose intolerance via hyperinsulinemia

  • Text
  • PDF
Abstract

Metabolic crosstalk from skeletal muscle to multiple organs is important for maintaining homeostasis, and its dysregulation can lead to various diseases. Chronic glucocorticoid administration often induces muscle atrophy and metabolic disorders such as diabetes and central obesity; however, the detailed underlying mechanism remains unclear. We previously reported that the deletion of glucocorticoid receptor (GR) in skeletal muscle increases muscle mass and reduces fat mass through muscle-liver-fat communication under physiological conditions. In this study, we show that muscle GR signaling plays a crucial role in accelerating obesity through the induction of hyperinsulinemia. Fat accumulation in liver and adipose tissue, muscle atrophy, hyperglycemia, and hyperinsulinemia induced by chronic corticosterone (CORT) treatment improved in muscle-specific GR-knockout (GR-mKO) mice. Such CORT-induced fat accumulation was alleviated by suppressing insulin production (streptozotocin injection), indicating that hyperinsulinemia enhanced by muscle GR signaling promotes obesity. Strikingly, glucose intolerance and obesity in ob/ob mice without CORT treatment were also improved in GR-mKO mice, indicating that muscle GR signaling contributes to obesity-related metabolic changes, regardless of systemic glucocorticoid levels. Thus, this study provides insight for the treatment of obesity and diabetes by targeting muscle GR signaling.

Authors

Hiroki Yamazaki, Masaaki Uehara, Noritada Yoshikawa, Akiko Kuribara-Souta, Motohisa Yamamoto, Yasuko Hirakawa, Yasuaki Kabe, Makoto Suematsu, Hirotoshi Tanaka

×

Figure 4

Muscle GR regulates the muscle transcriptome, alters plasma amino acid levels, and causes hyperglycemia and hyperinsulinemia in an obesity model induced by chronic CORT treatment.

Options: View larger image (or click on image) Download as PowerPoint
Muscle GR regulates the muscle transcriptome, alters plasma amino acid l...
(A) RNA-seq was performed using pooled RNA samples (n = 3) of gastrocnemius muscle (Gas) from GRfl/fl and GR-mKO mice treated with vehicle or CORT for 4 weeks. The levels of genes significantly induced or repressed by CORT in GRfl/fl mice are shown as a heatmap. (B) The levels of some GR downstream genes are shown. (C) Plasma amino acid levels from GRfl/fl and GR-mKO mice treated with vehicle or CORT for 4 weeks. Pooled plasma samples (n = 3) were used. (D) Blood glucose and (E) plasma insulin levels of fed or 24-hour-fasted GRfl/fl and GR-mKO mice treated with vehicle or CORT for 0, 1, or 4 weeks. In 24-hour-fasted mice, the levels at 4 weeks were evaluated. n = 5–12 fed in D; n = 5–7 fasted in D; n = 5–8 fed in E; n = 5–7 fasted in E. (F) A homeostasis model assessment for insulin resistance (HOMA-IR) of 24-hour-fasted GRfl/fl and GR-mKO mice treated with vehicle or CORT for 4 weeks (n = 5–7). (G) Plasma FGF21 levels in GRfl/fl and GR-mKO mice treated with vehicle or CORT for 4 weeks. The results under fed or 24-hour-fasted states are shown (n = 3–7). Data presented as mean ± SEM. In D–G, 2-way ANOVA with Tukey-Kramer post hoc test was performed. *P < 0.05. For the fed data in D and E, statistical differences were assessed in CORT at 0 weeks (0w) versus CORT 1w, CORT 0w versus CORT 4w, and Veh 4w versus CORT 4w in each genotype, and in GRfl/fl versus GR-mKO under each condition. In the fed data in E, data were log-transformed before statistical analysis.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts